12 Dec
2017
18:42 E.S.T.

Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials

Read more

04 Dec
2017
16:30 E.S.T.

Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer

Read more

04 Dec
2017
16:30 E.S.T.

Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development

Read more

20 Nov
2017
16:30 E.S.T.

Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy

Read more

13 Nov
2017
16:15 E.S.T.

Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017

Read more

06 Nov
2017
19:00 E.S.T.

FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

Read more

01 Nov
2017
16:15 E.S.T.

Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting

Read more

01 Nov
2017
16:15 E.S.T.

Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting

Read more

04 Oct
2017
16:30 E.S.T.

Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer

Read more

04 Sep
2017
22:30 E.S.T.

Cellectis to Participate in Upcoming Investor Conferences

Read more